Background Iron deficiency (ID) is common in patients with atrial fibrillation/flutter (AF), but its prognostic implications and optimal diagnostic criteria, particularly in those with and without ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...

Bagsværd, Denmark, 24 January 2025 – Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once ...

IMMvention partners with Novo Nordisk to co-develop oral therapies for sickle cell disease using BACH1 inhibitors. Novo Nordisk to handle further development, regulatory, and commercialization ...

“We are excited to partner with Novo Nordisk. This collaboration represents a significant milestone for IMMvention and reinforces our vision to address unmet needs in sickle cell disease and ...

Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co-develop oral treatments for the red blood cell disorder and other ...

Heart attacks stem from long-term unhealthy habits, but small daily adjustments can lower the risk. Protecting your heart doesn’t require drastic changes; it’s all about making better choices ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has approved Novo Nordisk’s semaglutide for heart disease and Eli Lilly’s ...

Bernard Arnault is once again in charge of Europe's most valuable company. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes ...

Ziltivekimab is under clinical development by Novo Nordisk and currently in Phase ... is under development for the treatment of chronic kidney disease and anemia, atherosclerotic cardiovascular ...